Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9552 |
High Similarity |
NPD7266 |
Discontinued |
0.8345 |
Intermediate Similarity |
NPD6190 |
Approved |
0.8255 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7914 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7778 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7778 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7748 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7673 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7655 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7655 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7622 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7619 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.758 |
Intermediate Similarity |
NPD37 |
Approved |
0.7576 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7576 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7547 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7547 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7547 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7547 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7545 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7394 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7379 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7376 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7372 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7337 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.732 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7312 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.731 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7279 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7278 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7234 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7234 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7206 |
Intermediate Similarity |
NPD969 |
Suspended |
0.7185 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7185 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7124 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7118 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7099 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7093 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7093 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7075 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7066 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD3455 |
Phase 2 |
0.7039 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7024 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7024 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7024 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7019 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7006 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6989 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD7095 |
Approved |
0.697 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6961 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD228 |
Approved |
0.6954 |
Remote Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6951 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6946 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6923 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6902 |
Remote Similarity |
NPD7680 |
Approved |
0.6901 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.689 |
Remote Similarity |
NPD2801 |
Approved |
0.689 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6887 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6883 |
Remote Similarity |
NPD5588 |
Approved |
0.6863 |
Remote Similarity |
NPD5314 |
Approved |
0.6863 |
Remote Similarity |
NPD6653 |
Approved |
0.6857 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD1511 |
Approved |
0.6853 |
Remote Similarity |
NPD9545 |
Approved |
0.6849 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6848 |
Remote Similarity |
NPD5402 |
Approved |
0.6846 |
Remote Similarity |
NPD5736 |
Approved |
0.6842 |
Remote Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD3059 |
Approved |
0.6842 |
Remote Similarity |
NPD3062 |
Approved |
0.6842 |
Remote Similarity |
NPD3061 |
Approved |
0.6842 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6842 |
Remote Similarity |
NPD3620 |
Phase 2 |
0.6824 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6797 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6797 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6795 |
Remote Similarity |
NPD5762 |
Approved |
0.6795 |
Remote Similarity |
NPD5763 |
Approved |
0.6788 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6788 |
Remote Similarity |
NPD1358 |
Approved |
0.6774 |
Remote Similarity |
NPD7033 |
Discontinued |
0.677 |
Remote Similarity |
NPD1512 |
Approved |
0.677 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6759 |
Remote Similarity |
NPD9384 |
Approved |
0.6759 |
Remote Similarity |
NPD9381 |
Approved |
0.6738 |
Remote Similarity |
NPD5283 |
Phase 1 |
0.6732 |
Remote Similarity |
NPD943 |
Approved |
0.6731 |
Remote Similarity |
NPD9570 |
Approved |
0.6731 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6728 |
Remote Similarity |
NPD5403 |
Approved |
0.6712 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6711 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6711 |
Remote Similarity |
NPD6798 |
Discontinued |
0.671 |
Remote Similarity |
NPD4536 |
Approved |
0.671 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.671 |
Remote Similarity |
NPD4538 |
Approved |
0.6709 |
Remote Similarity |
NPD4237 |
Approved |
0.6709 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6709 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6707 |
Remote Similarity |
NPD7028 |
Phase 2 |
0.6706 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6706 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6689 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6689 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6689 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6688 |
Remote Similarity |
NPD1933 |
Approved |
0.6687 |
Remote Similarity |
NPD3687 |
Approved |
0.6687 |
Remote Similarity |
NPD7819 |
Suspended |
0.6687 |
Remote Similarity |
NPD3686 |
Approved |
0.6687 |
Remote Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.6686 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6685 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6667 |
Remote Similarity |
NPD6663 |
Approved |
0.6667 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD7843 |
Approved |
0.6667 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD6385 |
Approved |
0.6667 |
Remote Similarity |
NPD3092 |
Approved |
0.6667 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD6386 |
Approved |
0.6648 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6648 |
Remote Similarity |
NPD6842 |
Approved |
0.6648 |
Remote Similarity |
NPD6841 |
Approved |
0.6648 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6646 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6646 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6646 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6645 |
Remote Similarity |
NPD2492 |
Phase 1 |
0.6645 |
Remote Similarity |
NPD5952 |
Clinical (unspecified phase) |
0.6643 |
Remote Similarity |
NPD7157 |
Approved |
0.6631 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6627 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6627 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6623 |
Remote Similarity |
NPD4140 |
Approved |
0.6623 |
Remote Similarity |
NPD826 |
Approved |
0.6623 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6623 |
Remote Similarity |
NPD9494 |
Approved |
0.6623 |
Remote Similarity |
NPD825 |
Approved |
0.6623 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6622 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6621 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6605 |
Remote Similarity |
NPD8389 |
Clinical (unspecified phase) |
0.6605 |
Remote Similarity |
NPD5401 |
Approved |
0.6604 |
Remote Similarity |
NPD3060 |
Approved |
0.6604 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6601 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6596 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6596 |
Remote Similarity |
NPD8319 |
Approved |
0.6594 |
Remote Similarity |
NPD3134 |
Approved |
0.6593 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6592 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6591 |
Remote Similarity |
NPD2934 |
Approved |
0.6591 |
Remote Similarity |
NPD2933 |
Approved |
0.6591 |
Remote Similarity |
NPD7039 |
Approved |
0.6591 |
Remote Similarity |
NPD7038 |
Approved |
0.6588 |
Remote Similarity |
NPD5494 |
Approved |
0.6584 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6582 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6577 |
Remote Similarity |
NPD9622 |
Approved |
0.6575 |
Remote Similarity |
NPD9268 |
Approved |
0.6562 |
Remote Similarity |
NPD3750 |
Approved |
0.6562 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6561 |
Remote Similarity |
NPD7999 |
Approved |
0.6561 |
Remote Similarity |
NPD4108 |
Discontinued |
0.6558 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6557 |
Remote Similarity |
NPD6534 |
Approved |
0.6557
|
Remote Similarity |
NPD6535 |
Approved |